Tamara Maes is cofounder, vice-president and CSO of Oryzon Genomics S.A. She obtained?a BSc in Chemistry and PhD in Biotechnology?from the University of Ghent, Belgium. After a post-doctoral research?in the CSIC in Barcelona Spain,?in 2000 she co-founded Oryzon together with Dr. Carlos Buesa, and has been Chief Scientific Officer since the companys inception. In 2008, the company launches its first proprietary drug discovery program directed against LSD1. By 2012, Oryzon has developed a global leadership position in the development of LSD1 inhibitors with potential uses in oncology and neurodegenerative disease. Oryzon was the first company to complete the pre-clinical to clinical transition. The company has?3 compounds in development, including the selective LSD1 inhibitor iadademstat (ORY-1001), in Phase IIa for AML and SCLC, and the dual LSD1/MAOB inhibitor vafidemstat?(ORY-2001), in Phase IIa in multiple sclerosis, mild to moderate Alzheimer's disease, as well as a basket trial in aggression.?Oryzon is publically traded on the Madrid Stock Exchange (Ticker: ORY) since December 2015.